Weekly pill could slow aging: early trial launches

NCT ID NCT05949658

Recruiting now Disease control Sponsor: University of Wisconsin, Madison Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This Phase 1 trial tests two drugs, sirolimus and everolimus, given once a week to healthy adults aged 55-89. The goal is to find the safest dose that might slow the aging process. Participants take the drug for 6 weeks and are monitored for side effects and drug levels in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sirolimus and everolimus (weekly oral doses)
What this could lead to: If successful, this could point toward a safe, weekly pill that slows the aging process and extends healthy lifespan.
What could go wrong: This is a very early Phase 1 trial with only 72 healthy participants over 17 weeks. The drugs may cause side effects or fail to show meaningful anti-aging effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AGING

Contacts and locations

Locations

University of Wisconsin
RECRUITING

Madison, Wisconsin, 53705, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.